Avaleht/Aktsiad/HUMA

HUMA

USD

Humacyte Inc. Common Stock

$1.330+0.030 (2.308%)

Reaalajas hind

Healthcare

Biotehnoloogia

Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$1.300

Kõrge

$1.340

Madal

$1.220

Maht

3.25M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

249.1M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

5.40M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $1.15Praegune $1.330Kõrge $6.77

Seotud uudised

13. okt 2025 · 12:06

Analyst Upgrades

BTIG Maintains Buy on Humacyte, Lowers Price Target to $6

BTIG analyst Ryan Zimmerman maintains Humacyte with a Buy and lowers the price target from $7 to $6.

Vaata rohkem

BTIG Maintains Buy on Humacyte, Lowers Price Target to $6

7. okt 2025 · 13:00

GlobeNewswire

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today

Vaata rohkem

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

6. okt 2025 · 18:01

Analyst Upgrades

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

D. Boral Capital analyst Jason Kolbert maintains Humacyte with a Buy and maintains $25 price target.

Vaata rohkem

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

29. sept 2025 · 12:00

GlobeNewswire

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus –

Vaata rohkem